Diltiazem did not prevent vasospasm after subarachnoid hemorrhage in this trial. While it slightly increased bleeding time, no adverse clinical effects or changes in rebleeding rates were observed, suggesting further study is not warranted.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: